ABL kinase domain mutations with selective resistance to newer-generation inhibitors in vitro
| Drug . | Less resistant . | More resistant . |
|---|---|---|
| Nilotinib | L248V, G250E, F359C, L384M, L387F | Y253H, E255K/(V), T315I |
| Dasatinib | L248V, Q252H, E255K/V, V299L | T315I, F317C/L/V |
| Drug . | Less resistant . | More resistant . |
|---|---|---|
| Nilotinib | L248V, G250E, F359C, L384M, L387F | Y253H, E255K/(V), T315I |
| Dasatinib | L248V, Q252H, E255K/V, V299L | T315I, F317C/L/V |
Data are derived from O'Hare et al55 ; Weisberg et al56 ; and Bradeen et al.57